of: Ford AC, and others. Amitriptyline at low-dose and titrated for irritable bowel syndrome as second-line treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet 2023; 402: 1773 – 1785. The ATLANTIS homepage carries information for GPs and patients on the research and how to manage the dose. GutsUK offers advice and support for people suffering conditions. We very much welcome this research and hope those in primary care embrace its findings and discuss this as an option for their IBS patients.” Alison Reid, CEO, The IBS Network GutsUK“IBS is a common long-term condition. Its symptoms fluctuate and can be hard for the person to manage. Life quality is worse for people with IBS than for some with other non-gut conditions. This is a big IBS study
group submissions from: Bowel Cancer UK, GutsUK and AMMF – The cholangiocarcinoma charity. Bowel Cancer UK and GutsUK are registered charities and AMMF is a charitable incorporated organisation. 9 • Bowel Cancer UK has received 2% pharmaceutical company funding in the past two years, including from the submitting company. GutsUK has received 1.1% pharmaceutical company funding in the past two
research grant from GutsUK/BSPGHAN/Falk Pharma GmbH; honoraria from Falk Phar-ma and AbbVie; educational grants from Nutricia, Abbott, and RD/Mead Johnson. Bredenoord received research funding from Nutricia, Norgine, Falk Pharma, Thelial, and SST; and received speaker and/or consulting fees from Laborie, Arena, EsoCap, Medtronic, Falk Pharma, Calypso Biotech, Alimentiv
toxicity, that can be given in peripheral units away from specialist centres. This may have benefits for patients who live in rural areas. Identification of patients for nivolumab requires testing for PD-L1, which may have service implications for pathology departments. Additional Patient and Carer Involvement We received patient group submissions from OCHRE, GutsUK Charity and Heartburn Cancer UK. All three organisations are registered charities. OCHRE has not received any pharmaceutical company funding in the past two years. GutsUK Charity has received 1.1% pharmaceutical company funding in the past two years, with none from the submitting company. Heartburn Cancer UK has received 5.95% pharmaceutical company funding in the past two years, including 8 from the submitting company
The following information reflects the views of the specified Patient Groups. We received patient group submissions from OCHRE and GutsUK Charity, which are both registered charities. OCHRE has not received any pharmaceutical company funding in the past two years. GutsUK Charity has received 1.2% pharmaceutical company funding in the past two years, with none from the submitting company
) and support for people with diverticular disease. The PSP was funded by GutsUK Charity and Bowel Research UK. The Diverticular Disease PSP Top 10 was published in February 2025. Further information Diverticular Disease PSP websiteFind out more by visiting the Diverticular Disease PSP website Articles and publicationsFind out about related publications from the Diverticular Disease PSP Next SectionTop 10
of advanced gastric cancer on the carers/family of patients is heavy and treatment with trifluridine/tipiracil is anticipated to help alleviate this through prolongation of independence for patients and a possible reduction in time spent in hospital. We received a patient group submission from GutsUK Charity, which is a registered charity. GutsUK Charity has received 1.8% pharmaceutical company funding in the past two years, with none from the submitting company. A representative from GutsUK Charity participated in the PACE meeting. The key points of their submission have been included in the full PACE statement considered by SMC. Summary of comparative health economic evidence The company submitted a cost-utility analysis for the evaluation of trifluridine/tipiracil versus BSC when positioned for use
monotherapy. This will reduce treatment discontinuations and hospital admissions to manage severe toxicities, enabling patients to live and function more independently and reduce the burden of care for their families. The introduction of nivolumab is not expected to have significant service implications. Additional Patient and Carer Involvement We received patient group submissions from GutsUK Charity and OCHRE, which are both registered charities. GutsUK Charity has received 1.8% pharmaceutical company funding in the past two years, with none from the submitting company. OCHRE has not received any pharmaceutical company funding in the past two years. Representatives from both organisations participated in the PACE meeting. The key points of their submissions have been included in the full PACE
-DQA1*05 and mitigated by concomitant immunomodulator use for both drugs. GutsUK, Crohn's and Colitis UK, Cure Crohn's Colitis, AbbVie, Merck Sharp and Dohme, Napp Pharmaceuticals, Pfizer, and Celltrion Healthcare.
Trust; NIHR Imperial Biomedical Research Centre; Crohn's and Colitis UK; GutsUK; National Core Studies Immunity Programme, UK Research and Innovation; and unrestricted educational grants from F Hoffmann-La Roche, Biogen, Celltrion Healthcare, Takeda, and Galapagos.
concentrations showed an independent effect of immunomodulator use on week 54 non-remission (odds ratio 0·56 [95% CI 0·38-0·83], p=0·004). Anti-TNF treatment failure is common and is predicted by low drug concentrations, mediated in part by immunogenicity. Clinical trials are required to investigate whether personalised induction regimens and treatment-to-target dose intensification improve outcomes. GutsUK
to antibiotics. Consultation with our patient co-applicant, patient advisory group, The British Liver Trust and GutsUK Charity have highlighted recurrent hospitalisation, over-use of antibiotics and fear of acquiring a 'super-bug' as being important priorities to patients. The results and study findings will be published in conjunction with patient support groups, the wider media and the NHS. The investigator
. Newcastle UniversityType and method of reviewEpidemiologic, Narrative synthesis, Systematic reviewAnticipated or actual start date05 June 2023Anticipated completion date05 June 2024Funding sources/sponsorsThis review is being funded through the COLO-COHORT study, which was awarded a £1.25 million GUTSUK Association of Medical Research Charities grant.Conflicts of interestAs well as this review